Aguiar, Pedro N., Jr.De Mello, Ramon AndradeHall, PeterTadokoro, Hakarude Lima, Gilberto2019-11-202019-11-202017-051750-743X1750-7448http://hdl.handle.net/10400.1/13131Aim: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is the tumor programmed death ligand one (PD-L1) expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. Methods: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. Results: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89). Conclusion: PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.engSolid tumorsNivolumabMetaanalysisGuidelinesSafetyDocetaxelTherapyNsclcjournal article10.2217/imt-2016-0150